Cell Therapy News

Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 achieved and maintained normal hemoglobin levels, according to early results of a phase 1/phase 2 trial.

Pawel Kalinski, MD, PhD, has been promoted to Jacobs family endowed chair of immunology at Roswell Park Comprehensive Cancer Center.

BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK virus-associated hemorrhagic cystitis after undergoing allogeneic hematopoietic stem cell transplantation.

Cellular therapies will play a key role in pancreatic cancer management despite challenges thus far in applying these treatments to solid tumors, according to a panel discussion during the virtual Alliance for Cancer Gene Therapy Summit.

An independent panel unanimously agreed that chimeric antigen receptor T-cell therapy provides clinical benefit superior to the current standard of care for patients with relapsed or refractory multiple myeloma.

The FDA cleared an investigational new drug application for MB-106, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory, CD20-positive B-cell malignancies.

Michel Sadelain, MD, PhD, will receive this year’s Outstanding Achievement Award from the American Society of Gene and Cell Therapy for his research on chimeric antigen receptors.

The additional distance that Americans must travel to receive chimeric antigen receptor T-cell therapy compared with other cancer treatments varies greatly by region, according to a study by health care consulting firm Avalere Health.

The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with relapsed or refractory B-cell malignancies, according to the agent’s manufacturer.

Marcos J. de Lima, MD, has been appointed to key leadership positions at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.